Vaxart (NASDAQ:VXRT) Shares Cross Below 200-Day Moving Average of $0.88

Vaxart, Inc. (NASDAQ:VXRT) passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.88 and traded as low as $0.63. Vaxart shares last traded at $0.66, with a volume of 1,919,722 shares traded.

Analyst Ratings Changes

Separately, B. Riley raised Vaxart from a “neutral” rating to a “buy” rating and set a $2.00 price objective on the stock in a research note on Wednesday, January 31st.

Vaxart Stock Performance

The company’s fifty day moving average price is $1.13 and its 200-day moving average price is $0.88. The stock has a market cap of $116.43 million, a P/E ratio of -1.14 and a beta of 0.44.

Vaxart (NASDAQ:VXRT) last released its earnings results on Thursday, March 14th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.03. The firm had revenue of $3.25 million during the quarter, compared to analyst estimates of $0.45 million. Vaxart had a negative net margin of 1,117.56% and a negative return on equity of 108.45%. Analysts anticipate that Vaxart, Inc. will post -0.45 earnings per share for the current fiscal year.

Institutional Trading of Vaxart

A number of large investors have recently made changes to their positions in VXRT. PFG Investments LLC bought a new stake in shares of Vaxart during the first quarter valued at approximately $38,000. Kingswood Wealth Advisors LLC bought a new stake in Vaxart during the 1st quarter valued at $32,000. Beacon Capital Management LLC raised its position in Vaxart by 369.9% during the 4th quarter. Beacon Capital Management LLC now owns 50,814 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 40,000 shares in the last quarter. Finally, AE Wealth Management LLC lifted its holdings in shares of Vaxart by 180.7% in the 3rd quarter. AE Wealth Management LLC now owns 62,113 shares of the biotechnology company’s stock worth $47,000 after buying an additional 39,987 shares during the period. 18.05% of the stock is owned by hedge funds and other institutional investors.

About Vaxart

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical dysplasia.